Is NewCardio Stock a Good Investment?
NewCardio Investment Advice | NWCI |
- Examine NewCardio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research NewCardio's leadership team and their track record. Good management can help NewCardio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Technology space and any emerging trends that could impact NewCardio's business and its evolving consumer preferences.
- Compare NewCardio's performance and market position to its competitors. Analyze how NewCardio is positioned in terms of product offerings, innovation, and market share.
- Check if NewCardio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about NewCardio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in NewCardio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if NewCardio is a good investment.
Not Rated
Examine NewCardio Stock
Researching NewCardio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if NewCardio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NewCardio's research are outlined below:
| NewCardio generated a negative expected return over the last 90 days | |
| NewCardio has some characteristics of a very speculative penny stock | |
| NewCardio currently holds 6.01 M in liabilities. NewCardio has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about NewCardio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 257.4 K. Net Loss for the year was (11.5 M) with profit before overhead, payroll, taxes, and interest of 105.1 K. | |
| NewCardio currently holds about 13.06 K in cash with (4.56 M) of positive cash flow from operations. | |
| NewCardio has a frail financial position based on the latest SEC disclosures |
NewCardio's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 49.72 K.Market Cap |
|
NewCardio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.73) | (4.96) | |
| Return On Capital Employed | 11.10 | 11.66 | |
| Return On Assets | (4.63) | (4.87) | |
| Return On Equity | 4.18 | 2.57 |
Determining NewCardio's profitability involves analyzing its financial statements and using various financial metrics to determine if NewCardio is a good buy. For example, gross profit margin measures NewCardio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NewCardio's profitability and make more informed investment decisions.
Evaluate NewCardio's management efficiency
NewCardio has return on total asset (ROA) of (2.2419) % which means that it has lost $2.2419 on every $100 spent on assets. This is way below average. NewCardio's management efficiency ratios could be used to measure how well NewCardio manages its routine affairs as well as how well it operates its assets and liabilities. The NewCardio's current Return On Capital Employed is estimated to increase to 11.66, while Return On Tangible Assets are projected to decrease to (4.96). As of now, NewCardio's Intangible Assets are increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.10) | (0.10) | |
| Tangible Book Value Per Share | (0.10) | (0.11) | |
| Enterprise Value Over EBITDA | (3.28) | (3.11) | |
| Price Book Value Ratio | (8.85) | (8.41) | |
| Enterprise Value Multiple | (3.28) | (3.11) | |
| Price Fair Value | (8.85) | (8.41) | |
| Enterprise Value | 24.1 M | 15.6 M |
NewCardio showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta (120.60) |
Basic technical analysis of NewCardio Stock
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NewCardio, as well as the relationship between them.NewCardio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewCardio insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewCardio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NewCardio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Farallon Capital Management Llc over a month ago Acquisition by Farallon Capital Management Llc of 445 shares of NewCardio at 0.01 subject to Rule 16b-3 | ||
Farallon Partners L L C/ca over two months ago Acquisition by Farallon Partners L L Cca of tradable shares of NewCardio at 0.01 subject to Rule 16b-3 | ||
Farallon Capital Management Llc over three months ago Acquisition by Farallon Capital Management Llc of tradable shares of NewCardio at 0.01 subject to Rule 16b-3 | ||
Farallon Partners L L C/ca over six months ago Acquisition by Farallon Partners L L Cca of tradable shares of NewCardio at 0.01 subject to Rule 16b-3 | ||
Farallon Partners L L C/ca over six months ago Acquisition by Farallon Partners L L Cca of 1012 shares of NewCardio at 0.01 subject to Rule 16b-3 | ||
Farallon Partners L L C/ca over six months ago Acquisition by Farallon Partners L L Cca of 1850 shares of NewCardio at 0.01 subject to Rule 16b-3 |
NewCardio's Outstanding Corporate Bonds
NewCardio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NewCardio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NewCardio bonds can be classified according to their maturity, which is the date when NewCardio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
NewCardio Stock media impact
Far too much social signal, news, headlines, and media speculation about NewCardio that are available to investors today. That information is available publicly through NewCardio media outlets and privately through word of mouth or via NewCardio internal channels. However, regardless of the origin, that massive amount of NewCardio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NewCardio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NewCardio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NewCardio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NewCardio alpha.
When determining whether NewCardio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NewCardio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Newcardio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Newcardio Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewCardio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in NewCardio Stock please use our How to Invest in NewCardio guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewCardio. If investors know NewCardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewCardio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.008 | Quarterly Revenue Growth (0.90) | Return On Assets (2.24) |
The market value of NewCardio is measured differently than its book value, which is the value of NewCardio that is recorded on the company's balance sheet. Investors also form their own opinion of NewCardio's value that differs from its market value or its book value, called intrinsic value, which is NewCardio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewCardio's market value can be influenced by many factors that don't directly affect NewCardio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between NewCardio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if NewCardio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewCardio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.